Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
Drug Therapy01:28

Drug Therapy

39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
39
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

618
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
618
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hallucinogen-Assisted Psychotherapy for Trauma Disorders: A Bionian Lens.

Psychodynamic psychiatry·2026
Same author

Bioprospecting and phylogenetic analysis of Priestia flexa AW3: an industrially significant amylase-producing bacterium from unexplored contaminated soil in Layyah.

Journal of industrial microbiology & biotechnology·2025
Same author

Income-based inequalities in risk factors of NCDs and inequities of preventive care services amongst 202,682 adults: a cross-sectional study of South Asia Biobank.

BMC medicine·2025
Same author

Characteristics and Outcomes of Patients with Self-directed Violence Presenting to Trauma Centers in the United States.

The western journal of emergency medicine·2025
Same author

Quantification of regional variation in ultra-processed food consumption and its sociodemographic correlates across Bangladesh, India, Pakistan, and Sri Lanka: insights from the South Asia Biobank.

The Lancet regional health. Southeast Asia·2025
Same author

Distribution of multidrug-resistant <i>Proteus mirabilis</i> in poultry, livestock, fish, and the related environment: One Health heed.

Veterinary world·2025

Related Experiment Video

Updated: Jun 6, 2025

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain
08:23

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain

Published on: May 12, 2018

9.5K

Agitation: Neurobiology and current management guidelines.

Christopher W T Miller1, Mario Rullo2, Sarah Van Remmen1

  • 1University of Maryland School of Medicine, 701 W. Pratt St, Rm 454 Baltimore, MD 21201, United States of America.

The American Journal of Emergency Medicine
|November 30, 2024
PubMed
Summary

Updated guidelines for managing agitation in emergency settings are available. This review covers neurobiology, pharmacology, and new treatments like ketamine and droperidol for effective patient care.

Keywords:
AgitationAntipsychoticBenzodiazepinesDexmedetomidineEmergency departmentKetamineNeurobiology

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.4K
A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice
07:18

A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice

Published on: March 2, 2019

19.0K

Related Experiment Videos

Last Updated: Jun 6, 2025

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain
08:23

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain

Published on: May 12, 2018

9.5K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.4K
A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice
07:18

A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice

Published on: March 2, 2019

19.0K

Area of Science:

  • Emergency Medicine
  • Neuroscience
  • Psychiatry

Background:

  • Agitation management in emergency settings requires updated guidelines.
  • Previous guidelines, Project BETA, were published in 2012.
  • Recent advancements include increased use of ketamine and droperidol.

Purpose of the Study:

  • Synthesize current recommendations for agitation management.
  • Detail the neurobiology of agitation.
  • Link neurobiology to pharmacological profiles of treatments.

Main Methods:

  • Literature review of current guidelines and research.
  • Analysis of neurobiological underpinnings of agitation.
  • Pharmacological profile assessment of key agents.

Main Results:

  • Current guidelines incorporate new evidence and treatments.
  • Ketamine and droperidol are increasingly utilized.
  • Understanding neurobiology informs drug selection.

Conclusions:

  • Updated strategies enhance the treatment of agitation.
  • Consideration of specific causes is crucial for effective management.
  • Evidence-based recommendations improve clinical practice.